toxylact: a05aa01 chenodesoxycholic acid

The first professional lActological database in the word

Chenodeoxycholic acid (ATC A05AA01) is a primary bile acid used orally for dissolution of cholesterol gallstones, with relevant but incompletely defined safety data in pregnancy and lactation that require a precautionary toxicological‑lactological approach.medpedia.framar+2

Classification and pharmacological profile

Chenodeoxycholic acid (also known as chenodiol) is a naturally occurring human bile acid belonging to ATC class A05AA “Bile acid preparations.”mims+1
It is a white crystalline substance, insoluble in water but soluble in alcohol and acetic acid, synthesized in the liver from cholesterol as one of the main primary bile acids.medpedia.framar+1
Pharmacodynamically, it suppresses hepatic synthesis of cholesterol and cholic acid, leading to biliary cholesterol desaturation and gradual dissolution of radiolucent cholesterol gallstones, without effect on radiopaque or pigment stones.mims+1

Indications, dosage and interactions (general clinical context)

Clinically, chenodeoxycholic acid is indicated primarily for oral dissolution of cholesterol‑rich gallstones in patients with a functioning gallbladder and radiolucent stones.medpedia.framar+1
Adult dosing regimens typically start at 250 mg twice daily, titrated weekly by 250 mg up to a recommended or maximally tolerated dose, with maintenance doses around 13–16 mg/kg/day in divided doses taken with food.mims
Major interactions include reduced absorption with bile acid sequestrants and aluminum‑containing antacids, reduced efficacy with estrogen and fibric acid derivatives, and potential enhancement of vitamin K antagonist anticoagulant effect; numerous clinically relevant interactions have been catalogued.medpedia.framar+1

Toxicological considerations

Chenodeoxycholic acid can cause gastrointestinal and hepatic adverse reactions, including diarrhea with fluid and electrolyte loss, reversible elevation of hepatic transaminases, and other digestive symptoms such as nausea, vomiting, abdominal pain and biliary colic.mims+1
Hepatic impairment, hepatocyte dysfunction, and bile ductal abnormalities are contraindications, and long‑term therapy has been associated with hepatotoxicity and a possible increased risk of colon neoplasia, necessitating careful monitoring of liver enzymes, cholesterol, and imaging of the biliary system.sciencedirect+1
Because of these toxicological risks and the need for intact hepatic metabolism and bile flow, chenodeoxycholic acid is reserved for selected patients, with avoidance in those with advanced liver disease or complex gallbladder pathology.sciencedirect+1

Pregnancy and lactation safety

Regulatory product information and expert reviews advise against the use of chenodeoxycholic acid in pregnancy due to limited data and potential risks, stating that it should not be used and that treatment in early pregnancy does not in itself mandate termination but should be avoided where possible.ema.europa+1
For breastfeeding, it is not known whether chenodeoxycholic acid or its metabolites are excreted in human milk, and labeling therefore cannot exclude a risk to newborns or infants, leading to recommendations that its use during lactation is not advised or should proceed only if clearly necessary.pharmaline+1
Specialized lactation resources classify chenodeoxycholic acid as very low risk and compatible with breastfeeding, but they still suggest follow‑up and clinical vigilance because of limited direct milk measurement data and the drug’s bile acid activity in the infant gastrointestinal tract.ncbi.nlm.nih+1

Lactological positioning within bile acid therapy

Within bile acid therapy, chenodeoxycholic acid (A05AA01) is pharmacologically effective for gallstone dissolution but comparatively less favored in women of childbearing age and nursing mothers than ursodeoxycholic acid, which has more robust evidence of negligible transfer to breast milk and safety in breastfed infants.pmc.ncbi.nlm.nih+2
Given the absence of quantified milk levels for chenodeoxycholic acid and the presence of safer alternatives, a cautious lactological approach is to avoid initiating chenodeoxycholic acid in breastfeeding women when ursodeoxycholic acid or non‑bile‑acid strategies are suitable, or to use chenodeoxycholic acid only under specialist supervision with infant monitoring.e-lactation+2
In toxicological‑lactological databases, chenodeoxycholic acid should therefore be documented as a bile acid gallstone‑dissolution agent with hepatotoxic potential, contraindicated in pregnancy, and of uncertain but probably low lactation risk, with clear preference for better‑studied bile acids in breastfeeding patients.publications.cuni+2

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.